ad image

FDA Orphan Drug Designation

1 / 1
BioInvent
FDA

BioInvent Receives FDA Orphan Designation for BI-1206 for Mantle Cell Lymphoma

BioInvent

PR-M01-19-NI-088Jan 30, 2019
Martin Pharmaceuticals
Drug Designation

Martin Pharmaceuticals’ LIVANTRA™ Receives FDA Orphan Drug Designation in Second Indication

Martin Pharmaceuticals

PR-M09-18-NI-033Sep 13, 2018
Pliant Therapeutics
FDA Orphan Drug Designation

Pliant Therapeutics Receives FDA Orphan Drug Designation for Lead Program PLN-74809 in Idiopathic Pulmonary Fibrosis

Pliant Therapeutics

PR-M08-18-NI-058Aug 15, 2018
Processa Pharmaceuticals, Inc.
Orphan Drug

Processa Pharmaceuticals Receives Orphan Designation Status For PCS499 In Necrobiosis Lipoidica From The Food And Drug Administration (FDA)

Processa Pharmaceuticals, Inc.

PR-M06-18-NI-079Jun 25, 2018
Samus Therapeutics
Orphan Drug

Samus Therapeutics Announces PU-H71 Granted Orphan Drug Designation and First Patient Dosed in Phase 1b Study in Myelofibrosis

Samus Therapeutics

PR-M06-18-NI-050Jun 14, 2018
Genea Biocells
Drug Designation

Genea Biocells Announces FDA Orphan Drug Designation for GBC0905 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)

Genea Biocells

PR-M06-18-NI-016Jun 06, 2018
1 / 1